Quality control for tumor tissue bank of gastrointestinal tract carcinoma

Platelet aggregation was studied in 73 patients with carcinoma of gastrointestinal tract. Control group was composed of 45 patients with non malignant diseases. Aggregation was induced by adding 10μg/ml of Collagen, 1μ or 2μM at final concentration of ADP to that platelet rich plasma. Using aggregometer of Bryston, aggregation curves were recorded. The estimation of platelet aggregation was determined by aggregation rate, disaggregation rate and maximum aggregation rate. Patients with carcinoma were divided into two groups according to the presence of peritoneal dissemination, liver metastasis, lymphnode involvement as well as the depth of cancer invasion ( limited within submucosa layer or invaded below proper muscle ) and the size ( ≤ 5 cm or > 5 cm ). Moreover after resection of tumor, alteration in parameters of platelet aggregation was evaluated. Maximum aggregation rate was higher and disaggregation rate was lower in patients with carcinoma than in control group. There was significant differences in the intensity of platelet aggregation according to the rate of invasion and the size of the tumor, although peritoneal dissemination, liver metastasis, or lymphnode involvement did not affect platelet aggregation. Maximum aggregation rate and aggregation rate were higher and disaggregation rate was lower in the group with deeper invasion of tumor as well as in the group with larger tumors. After removal of tumor, platelet aggregation decreased. These results suggested that a substance or substances which activate platelet aggregation would be released from tumor tissue.

Download Full-text

Prognostic value of MAGE-A3 and PRAME gene expression in non-small-cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.7056 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. 7056-7056 ◽

Cited By ~ 4

Author(s):

Albert Linder ◽

Henry Budihardjo-Welim ◽

Wiorika Velehorschi ◽

Thierry Coche ◽

Olivier Gruselle ◽

...

Keyword(s):

Prognostic Value ◽

Tumor Tissue ◽

Tissue Bank ◽

Disease Free Survival ◽

Stage I ◽

Stage Iiib ◽

Phase Iii ◽

Stage Ib ◽

Expression Rate ◽

Disease Free

7056 Background: We investigated the expression of some cancer–testis genes and their association with disease prognosis. Here we report our results for the expression, in resected NSCLC samples, of two tumor-specific antigens (Ags): MAGE‑A3 and PRAME, both under evaluation in clinical trials. Methods: We conducted a single-center, uncontrolled, retrospective study of tissue from resected stage I–III NSCLC patients (pts): 650 were in stage I, 215 in stage II and 395 in stage III. 1260 FFPE tumor tissue samples from the tumor tissue bank of the Department of Pathology, Lungenklinik Hemer (Germany), were tested for MAGE‑A3 and PRAME expression by specific qRT-PCR assays. The prognostic value of these Ags was determined by estimating the median overall survival (OS), disease-free interval (DFI) and disease-free survival (DFS). Results: Expression rates were 36% for MAGE‑A3 and 66% for PRAME. The co‑expression rate was 30%. Almost all tumors expressing MAGE‑A3 also expressed PRAME. We observed no difference overall in Ag expression according to stage, tumor size and pts’ age. Squamous tumors expressed MAGE‑A3 and PRAME more frequently than did adenocarcinomas (43 vs. 27 % and 80 vs. 44% respectively), and PRAME expression rates were higher in males than in females (70 vs. 53%). In the overall population, which included stages IA–IIIB, no prognostic value was detected for the expression of either Ag. In subset analyses, we found in 83 stage IIIB pts a trend to worse OS linked to MAGE‑A3 expression (HR=1.977, p=0.0312). In 395 stage IB pts, PRAME expression was associated with worse OS (HR=1.483, p=0.0344) and DFS (HR=1.492, p=0.0167). Conclusions: The MAGE‑A3 expression rate found is consistent with the results observed in the phase III MAGRIT trial (J‑H Kim et al., 2011). No prognostic value for either PRAME or MAGE‑A3 was observed in the overall population, in contrast to previous reports with smaller sample sizes (Gure et al., 2005, Boli et al., 2002) and in other tumors (Vourch’jourdain et al., 2009, Epping et al., 2008). We observed a trend toward poor prognostic value of MAGE‑A3 in stage IIIB pts and of PRAME in stage IB pts.

Download Full-text

UCLA/USC Tumor Tissue Bank

10.21236/ada371370 ◽

1998 ◽

Author(s):

Dennis J. Slamon

Keyword(s):

Tumor Tissue ◽

Tissue Bank

Download Full-text

Iris metastasis as the initial presentation of upper gastrointestinal tract carcinoma: a case report

Journal of Medical Case Reports ◽

10.1186/s13256-019-2303-5 ◽

2019 ◽

Vol 13 (1) ◽

Cited By ~ 1

Author(s):

M. A. Rehman Siddiqui ◽

Syed Zohaib Maroof Hussain ◽

Muhammed Mubarak

Keyword(s):

Gastrointestinal Tract ◽

Primary Source ◽

Upper Gastrointestinal Tract ◽

Prior History ◽

Initial Manifestation ◽

Iris Metastasis ◽

History Of ◽

Gastrointestinal Tract Carcinoma ◽

Upper Gastrointestinal ◽

Systemic Malignancy

Abstract Background We report a case of a patient with iris metastasis as the initial manifestation of a systemic cancer: upper gastrointestinal tract carcinoma. Case presentation A 24-year-old Asian man presented to our hospital with complaints of red left eye, decreased visual acuity, pain, and photophobia for about 3 weeks with no prior history of cancer or any other medical abnormality. Ocular examination showed a pinkish white lesion on the superonasal part of the iris. The patient’s intraocular pressure was progressively increasing despite medications, followed by lymphadenopathy 4 weeks later. Comprehensive examination was performed along with a complete systemic workup, which detected systemic malignancy. Histopathology and immunohistochemistry revealed signet ring cells, which indicated an upper gastrointestinal tract tumor as a primary source of iris metastasis. The systemic condition of the patient deteriorated rapidly thereafter and led to his death in the 12th week of the disease. Conclusion A red eye with iris lesions in otherwise healthy individuals should be considered as a possible initial manifestation of underlying systemic malignancy. Prompt referral of such patients to an oncologist is warranted.

Download Full-text